NCT02218294View on ClinicalTrials.gov

Study to Determine How BCX4161 is Metabolized and Eliminated by the Body

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Hereditary Angioedema
Interventions
DRUG

BCX4161

Trial Locations (1)

NG11 6JS

Quotient Clinical Ltd, Ruddington

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY

NCT02218294 - Study to Determine How BCX4161 is Metabolized and Eliminated by the Body | Biotech Hunter | Biotech Hunter